Stumble For Vical/Astellas CMV Vaccine In Kidney Transplants

Vical and Astellas have unveiled disappointing topline Phase II results with their cytomegalovirus vaccine in kidney transplant patients, although the product remains on track in the hematopoietic cell transplant setting.